A state initiative to reduce intermediaries in China’s pharmaceutical market is expected to more than halve the number of companies in the sector, but experts say the government will struggle to achieve its aim of cutting drug prices and tackling bribery in distribution chains.
中國政府一項縮減醫藥市場中間環節的計劃，有望使該領域的企業數量減少一半以上，但專家們表示，政府將很難實現其壓低藥價、清除分銷鏈條中賄賂行為的目標。
您已閱讀7%（351字），剩余93%（4825字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。